ArticleLeukemia research reports2025

Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia.

Aneta Strumilowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.